AstraZeneca and Johnson & Johnson, two famous pharmaceutical companies are set to resume their paused COVID-19 phase 3 vaccine trials In the United States.
US food and drug administration, following global data revision and safety conclusion have reportedly authorized both of the companies to proceed with the previously stopped phase 3 of vaccine trials.
AstraZeneca’s trials were halted when a volunteer suffered from a neurological condition after receiving the second dose of the Trial vaccine, meanwhile, Johnson & Johnson trials were stopped, when a participant developed an unexplained illness. No clear cause is yet identified.
This comes as Moderna company launched the First large-scale US Covid-19 vaccine trial that reaches a target enrollment of 30,000 participants.
Reports indicate that 53 out of 30,000 participants need to be sick with COVID-19, and 40 out of 53 infected volunteers need to be participants who received the placebo. This will show 75% effectiveness of the vaccine.